stockportfolio.pro
Stocks / JNJ vs MRK
JNJ vs MRK
Johnson & Johnson and Merck & Co., Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Johnson & Johnson (JNJ) | Merck & Co., Inc. (MRK) | |
|---|---|---|
| Market cap | $567.3B | $283.8B |
| Revenue (latest FY) | $94.19B | $65.01B |
| Net income (latest FY) | $26.80B | $18.25B |
| Revenue growth (5y CAGR) | 2.7% | 9.4% |
| Net margin | 28.5% | 28.1% |
| Return on equity | 32.9% | 34.7% |
| P/E ratio | 27.9 | 32.4 |
| Dividend yield | 2.2% | 2.9% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open JNJ — free Open MRK — freeFrequently asked questions
Which is bigger, JNJ or MRK?
Johnson & Johnson is larger by market capitalization — $567.3B versus $283.8B.
Which grows faster, JNJ or MRK?
Over the last five fiscal years, Merck & Co., Inc. grew revenue faster — 9.4%/yr versus 2.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.